{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T10:38:55Z","timestamp":1790419135808,"version":"4.1.0"},"reference-count":62,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2014,4,10]],"date-time":"2014-04-10T00:00:00Z","timestamp":1397088000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosntds.org"],"crossmark-restriction":false},"short-container-title":["PLoS Negl Trop Dis"],"DOI":"10.1371\/journal.pntd.0002790","type":"journal-article","created":{"date-parts":[[2014,4,10]],"date-time":"2014-04-10T16:56:35Z","timestamp":1397148995000},"page":"e2790","update-policy":"https:\/\/doi.org\/10.1371\/journal.pntd.corrections_policy","source":"Crossref","is-referenced-by-count":92,"title":["Broad Spectrum Antiviral Activity of Favipiravir (T-705): Protection from Highly Lethal Inhalational Rift Valley Fever"],"prefix":"10.1371","volume":"8","author":[{"given":"Amy L.","family":"Caroline","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana S.","family":"Powell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura M.","family":"Bethel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim D.","family":"Oury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas S.","family":"Reed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy L.","family":"Hartman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2014,4,10]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.antiviral.2013.03.014","article-title":"Influenza virus resistance to neuraminidase inhibitors","volume":"98","author":"M Samson","year":"2013","journal-title":"Antiviral Res"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.antiviral.2013.08.023","article-title":"Neuraminidase inhibitors for influenza B virus infection: Efficacy and resistance","volume":"100","author":"AJ Burnham","year":"2013","journal-title":"Antiviral Research"},{"key":"ref3","unstructured":"FujiFilm Pharmaceuticals U.S.A Inc. (2011\u20132013) Pharmacokinetics of Favipiravir in Volunteers With Hepatic Impairment. In: ClinicalTrials.gov, editor. Bethesda, MD: National Library of Medicine."},{"key":"ref4","unstructured":"FujiFilm Pharmaceuticals U.S.A Inc. (2010\u20132012) Dose-Finding Study of Favipiravir in the Treatment of Uncomplicated Influenza. In: ClinicalTrials.gov, editor. US: National Library of Medicine."},{"key":"ref5","unstructured":"FujiFilm Pharmaceuticals U.S.A Inc., and Department of Defense. (2012\u20132013) T-705a Multicenter Study in Adults Subjects With Uncomplicated Influenza (FAVOR). In: ClinicalTrials.gov, editor. US: National Library of Medicine."},{"key":"ref6","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1073\/pnas.0909603107","article-title":"T-705 (favipiravir) activity against lethal H5N1 influenza A viruses","volume":"107","author":"M Kiso","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1128\/AAC.49.3.981-986.2005","article-title":"Mechanism of action of T-705 against influenza virus","volume":"49","author":"Y Furuta","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"e3725","DOI":"10.1371\/journal.pone.0003725","article-title":"Treatment of late stage disease in a model of arenaviral hemorrhagic fever: T-705 efficacy and reduced toxicity suggests an alternative to ribavirin","volume":"3","author":"BB Gowen","year":"2008","journal-title":"PLoS One"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1128\/AAC.00356-07","article-title":"In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections","volume":"51","author":"BB Gowen","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.antiviral.2009.10.015","article-title":"Efficacy of favipiravir (T-705) and T-1106 pyrazine derivatives in phlebovirus disease models","volume":"86","author":"BB Gowen","year":"2010","journal-title":"Antiviral Res"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1128\/AAC.01074-08","article-title":"Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106","volume":"53","author":"JG Julander","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.antiviral.2009.02.201","article-title":"Effect of T-705 treatment on western equine encephalitis in a mouse model","volume":"82","author":"JG Julander","year":"2009","journal-title":"Antiviral Res"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.antiviral.2008.07.009","article-title":"Efficacy of orally administered T-705 pyrazine analog on lethal West Nile virus infection in rodents","volume":"80","author":"JD Morrey","year":"2008","journal-title":"Antiviral Res"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3851\/IMP1729","article-title":"Maporal virus as a surrogate for pathogenic New World hantaviruses and its inhibition by favipiravir","volume":"21","author":"KK Buys","year":"2011","journal-title":"Antivir Chem Chemother"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.antiviral.2009.02.198","article-title":"T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections","volume":"82","author":"Y Furuta","year":"2009","journal-title":"Antiviral Res"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"4673","DOI":"10.1128\/AAC.00886-13","article-title":"Antiviral efficacy of favipiravir against two prominent etiological agents of hantavirus pulmonary syndrome","volume":"57","author":"D Safronetz","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1128\/AAC.01219-10","article-title":"T-705 (favipiravir) inhibition of arenavirus replication in cell culture","volume":"55","author":"M Mendenhall","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"e1342","DOI":"10.1371\/journal.pntd.0001342","article-title":"Effective oral favipiravir (T-705) therapy initiated after the onset of clinical disease in a model of arenavirus hemorrhagic Fever","volume":"5","author":"M Mendenhall","year":"2011","journal-title":"PLoS Negl Trop Dis"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1089\/vbz.2010.0245","article-title":"The status of Rift Valley fever in animals in Saudi Arabia: a mini review","volume":"11","author":"AI Al-Afaleq","year":"2011","journal-title":"Vector Borne Zoonotic Dis"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"52","DOI":"10.4269\/ajtmh.2010.09-0291","article-title":"An assessment of the regional and national socio-economic impacts of the 2007 Rift Valley fever outbreak in Kenya","volume":"83","author":"KM Rich","year":"2010","journal-title":"Am J Trop Med Hyg"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"161","DOI":"10.4081\/gh.2012.134","article-title":"A temperature-limited assessment of the risk of Rift Valley fever transmission and establishment in the continental United States of America","volume":"6","author":"SK Konrad","year":"2012","journal-title":"Geospat Health"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1111\/1469-0691.12163","article-title":"Relevance of Rift Valley fever to public health in the European Union","volume":"19","author":"V Chevalier","year":"2013","journal-title":"Clinical Microbiology and Infection"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/1297-9716-44-58","article-title":"The transmission potential of Rift Valley fever virus among livestock in the Netherlands: A modelling study","volume":"44","author":"EA Fischer","year":"2013","journal-title":"Vet Res"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"363","DOI":"10.2987\/11-6169.1","article-title":"Potential for Canadian mosquitoes to transmit rift valley fever virus 1","volume":"27","author":"M Iranpour","year":"2011","journal-title":"Journal of the American Mosquito Control Association"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1603\/ME13049","article-title":"Potential for mosquitoes (Diptera: Culicidae) from Florida to transmit Rift valley fever virus","volume":"50","author":"MJ Turell","year":"2013","journal-title":"Journal of Medical Entomology"},{"key":"ref26","first-page":"e1","article-title":"Potential Effects of Rift Valley Fever in the United States","volume":"17","author":"DM Hartley","year":"2011","journal-title":"Emerg Infect Dis"},{"key":"ref27","unstructured":"NIAID (2013) NIAID Category A, B, and C Priority Pathogens. Accessed 11\/7\/2013. Available at: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.niaid.nih.gov\/topics\/biodefenserelated\/biodefense\/pages\/cata.aspx\" xlink:type=\"simple\">http:\/\/www.niaid.nih.gov\/topics\/biodefenserelated\/biodefense\/pages\/cata.aspx<\/ext-link>."},{"key":"ref28","first-page":"13294","article-title":"42 CFR Parts 72, 73 and 42 CFR Part 1003. Posession, Use, and Transfer of Select Agents and Toxins; final rule","volume":"70","year":"2005","journal-title":"Federal Register"},{"key":"ref29","first-page":"13241","article-title":"7 CFR Part 331 and 9 CFR Part 121. Agricultural Bioterrorism Protection Act of 2002; posession, use, and transfer of biological agents and toxins; final rule","volume":"70","year":"2005","journal-title":"Federal Register"},{"key":"ref30","unstructured":"Department of Health and Human Services (2009) Biosafety in Microbiological and Biomedical Laboratories. Washington, DC: U.S. Government Printing Office."},{"key":"ref31","doi-asserted-by":"crossref","first-page":"105","DOI":"10.3389\/fcimb.2012.00105","article-title":"Choice of inbred rat strain impacts lethality and disease course after respiratory infection with Rift Valley Fever Virus","volume":"2","author":"JM Bales","year":"2012","journal-title":"Front Cell Infect Microbiol"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.virol.2007.01.046","article-title":"Rift Valley fever virus lacking NSm proteins retains high virulence in vivo and may provide a model of human delayed onset neurologic disease","volume":"362","author":"BH Bird","year":"2007","journal-title":"Virology"},{"issue":"4","key":"ref33","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1128\/JVI.02341-13","article-title":"Aerosolized Rift Valley Fever virus causes fatal encephalitis in African green monkeys and common marmosets","volume":"88","author":"AL Hartman","year":"2014","journal-title":"Journal of Virology"},{"key":"ref34","first-page":"21","article-title":"Pathogenesis of Rift Valley Fever","volume":"3","author":"CJ Peters","year":"1981","journal-title":"Contr Epidem Biostatist"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/jmv.1890100107","article-title":"Inbred rat strains mimic the disparate human response to Rift Valley fever virus infection","volume":"10","author":"CJ Peters","year":"1982","journal-title":"J Med Virol"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/0882-4010(87)90126-4","article-title":"Pathogenesis of Rift Valley fever virus (RVFV) in inbred rats","volume":"2","author":"GW Anderson Jr","year":"1987","journal-title":"Microb Pathog"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/0882-4010(88)90096-4","article-title":"Viral determinants of virulence for Rift Valley fever (RVF) in rats","volume":"5","author":"GW Anderson Jr","year":"1988","journal-title":"Microb Pathog"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/0035-9203(79)90006-3","article-title":"Epidemic Rift Valley fever in Egypt: observations of the spectrum of human illness","volume":"73","author":"LW Laughlin","year":"1979","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/0035-9203(79)90004-X","article-title":"The Rift Valley fever epizootic in Egypt 1977\u201378. 1. Description of the epizootic and virological studies","volume":"73","author":"JM Meegan","year":"1979","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/0035-9203(78)90134-7","article-title":"Rift Valley Fever virus infections in Egypt: Pathological and virological findings in man","volume":"72","author":"KS Abdel-Wahab","year":"1978","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/0264-410X(91)90285-E","article-title":"Efficacy of a Rift Valley fever virus vaccine against an aerosol infection in rats","volume":"9","author":"GW Anderson Jr","year":"1991","journal-title":"Vaccine"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.coviro.2013.03.001","article-title":"Intervention strategies for emerging viruses: use of antivirals","volume":"3","author":"Y Debing","year":"2013","journal-title":"Curr Opin Virol"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1517\/14656566.2.8.1317","article-title":"Ribavirin\u2013current status of a broad spectrum antiviral agent","volume":"2","author":"NJ Snell","year":"2001","journal-title":"Expert Opin Pharmacother"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/0166-3542(86)90024-0","article-title":"Prophylaxis of Rift Valley fever with antiviral drugs, immune serum, an interferon inducer, and a macrophage activator","volume":"6","author":"CJ Peters","year":"1986","journal-title":"Antiviral Res"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1128\/AAC.26.4.476","article-title":"Synergistic antiviral effects of ribavirin and the C-nucleoside analogs tiazofurin and selenazofurin against togaviruses, bunyaviruses, and arenaviruses","volume":"26","author":"JW Huggins","year":"1984","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1128\/AAC.27.6.903","article-title":"Enhanced efficacy of liposome-encapsulated ribavirin against Rift Valley fever virus infection in mice","volume":"27","author":"M Kende","year":"1985","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1128\/AAC.31.7.986","article-title":"Enhanced therapeutic efficacy of poly(ICLC) and ribavirin combinations against Rift Valley fever virus infection in mice","volume":"31","author":"M Kende","year":"1987","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1128\/AAC.24.3.353","article-title":"Broad-spectrum antiviral activity of 2-beta-D-ribofuranosylselenazole-4-carboxamide, a new antiviral agent","volume":"24","author":"JJ Kirsi","year":"1983","journal-title":"Antimicrob Agents Chemother"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"S750","DOI":"10.1093\/clinids\/11.Supplement_4.S750","article-title":"Prospects for treatment of Viral Hemorrhagic Fevers with Ribavirin, a broad-spectrum antiviral drug","volume":"11","author":"JW Huggins","year":"1989","journal-title":"Reviews of Infectious Diseases"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1001\/jama.287.18.2391","article-title":"Hemorrhagic fever viruses as biological weapons: medical and public health management","volume":"287","author":"L Borio","year":"2002","journal-title":"JAMA"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.virol.2010.08.016","article-title":"The pathogenesis of Rift Valley fever virus in the mouse model","volume":"407","author":"DR Smith","year":"2010","journal-title":"Virology"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.antiviral.2013.03.009","article-title":"Post-exposure vaccination with MP-12 lacking NSs protects mice against lethal Rift Valley fever virus challenge","volume":"98","author":"BB Gowen","year":"2013","journal-title":"Antiviral Res"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"e2156","DOI":"10.1371\/journal.pntd.0002156","article-title":"Aerosol exposure to Rift Valley fever virus causes earlier and more severe neuropathology in the murine model, which has important implications for therapeutic development","volume":"7","author":"C Reed","year":"2013","journal-title":"PLoS Negl Trop Dis"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1006\/viro.1995.1197","article-title":"Mechanism of neuroinvasion of Venezuelan equine encephalitis virus in the mouse","volume":"208","author":"PC Charles","year":"1995","journal-title":"Virology"},{"key":"ref55","first-page":"399","article-title":"Mode of entry of a neurotropic arbovirus into the central nervous system. Reinvestigation of an old controversy","volume":"48","author":"TP Monath","year":"1983","journal-title":"Lab Invest"},{"key":"ref56","unstructured":"Martin JW, Christopher GW, Eitzen EM, Jr. (2008) History of Biological Weapons: From Poisoned Darts to Intentional Epidemics. Medical Aspects of Biological Warfare. Washington, DC: Borden Institute."},{"key":"ref57","first-page":"37988","article-title":"21 CFR Parts 314 and 601. Evidence Needed to Demonstrate Effectiveness of New Drugs When Human Efficacy Studies are Not Ethical or Feasible; final rule","volume":"67","year":"2002","journal-title":"Federal Register"},{"key":"ref58","unstructured":"National Research Council and the Committee on Animal Models for Assessing Countermeasures to Bioterrorism Agents (2011) Animal Models for Assessing Countermeasures to Bioterrorism Agents: The National Academies Press."},{"key":"ref59","unstructured":"Food and Drug Administration (February 5, 2003) FDA approves pyridostigmine bromide as pretreatment against nerve gas. Available at: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.fda.gov\/newsevents\/newsroom\/pressannouncements\/ucm130342\" xlink:type=\"simple\">http:\/\/www.fda.gov\/newsevents\/newsroom\/pressannouncements\/ucm130342<\/ext-link>"},{"key":"ref60","unstructured":"Food and Drug Administration (December 15, 2006) FDA approves drug to treat cyanide poisoning. Available at: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.fda.gov\/newsevents\/newsroom\/pressannouncements\/2006\/ucm108807\" xlink:type=\"simple\">http:\/\/www.fda.gov\/newsevents\/newsroom\/pressannouncements\/2006\/ucm108807<\/ext-link>"},{"key":"ref61","unstructured":"Food and Drug Administration (April 27, 2012) FDA approves new antibacterial treatment for plague. Available at: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.fda.gov\/newsevents\/newsroom\/pressannouncements\/ucm302220.htm\" xlink:type=\"simple\">http:\/\/www.fda.gov\/newsevents\/newsroom\/pressannouncements\/ucm302220.htm<\/ext-link>"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"e959","DOI":"10.1371\/journal.pntd.0000959","article-title":"Levofloxacin cures experimental pneumonic plague in African Green monkeys","volume":"5","author":"RC Layton","year":"2011","journal-title":"PLoS Negl Trop Dis"}],"container-title":["PLoS Neglected Tropical Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pntd.0002790","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T22:34:56Z","timestamp":1588977296000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0002790"}},"subtitle":[],"editor":[{"given":"Maya","family":"Williams","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2014,4,10]]},"references-count":62,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2014,4,10]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pntd.0002790","relation":{},"ISSN":["1935-2735"],"issn-type":[{"value":"1935-2735","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4,10]]}}}